semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Acne Vulgaris Males and females ≥ 12 years old Subjects must be in good general health as confirmed by medical history and physical examination Females of child-bearing potential must have a negative urine pregnancy test at the baseline visit and agree to be abstinent or use adequate birth control during the study (oral contraceptives, Norplant, Depo-Provera, or double barrier methods (e.g., condom and spermicide) Clear diagnosis of facial acne vulgaris for at least 6 months Subject must have a static Physician's Global Assessment (PGA) of 2 (mild severity) or 3 (moderate severity) Disease must be stable or slowly worsening for more than one week prior to entering the study Subjects or their guardians must be able to read, sign, and date the informed consent, and abide by study restrictions for its duration  Females who are pregnant, attempting to conceive, or breastfeeding Subjects with known hypersensitivity to any ingredients in the study drugs Subjects with overt signs of skin atrophy, telangiectasias or other skin findings that would affect efficacy evaluation Subjects with a current active skin malignancy or infection Subjects requiring the use of medications known to alter the course of acne vulgaris during the study treatment Subjects who have received systemic antibiotics within 2 weeks Subjects using systemic corticosteroids or immunosuppressants within 28 days of entering the study Subjects who have received any topical therapies for acne vulgaris within 7 days of entering the study Subjects taking birth control pills used solely for acne control Subjects who are currently participating in or, within the previous 28 days, have participated in another study for the treatment of acne vulgaris
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 1.0-13.0,  Developmental Disabilities Child aged 1-13 years old with development disabilities Currently tolerating enteral feeding Requiring nutritional management to meet 50-90th% weight for age on the Kennedy Kreiger Growth Charts Requires enteral tube feeding for at least 14 days  Unable to access gastrointestinal tract for feeding via tube Other condition which contraindicates tube feeding
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.115-999.0,  Genetic Disorder Infertility Hypogonadism Amenorrhea The essential 1. failure to go through a normal, age-appropriate, spontaneous puberty and low sex steroid levels in the setting of low/normal gonadotropins (due to substantial variability among patient presentations, this will be based on the clinical judgement of the Investigator), or 2. abnormally early development of puberty, or 3. normal puberty with subsequent development of low gonadotropin levels, or 4. pre-pubertal individuals with features suggestive of hypogonadotropic hypogonadism. 5. Family members: both affected and unaffected family members are strongly encouraged to participate  Since hypogonadotropic hypogonadism is a rare condition, this protocol remains open to enrollment so that we may study all subjects that are both qualified and interested in participating. Because HH represents a spectrum, where associated clinical findings may provide phenotypic clues to the assessment of inheritability and underlying physiology are very limited Patients who have additional pituitary deficiencies, effectively ruling out isolated GnRH deficiency, whether these deficiencies are congenital or acquired (e.g. secondary to malignancy, infection, or irradiation) Patients who are taking medications known to affect GnRH secretion, such as corticosteroids or continuous opiate administration (or were taking them at the time of diagnosis)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-17.0,  Growth Hormone Disorder Growth Hormone Deficiency in Children Diagnosis of short stature (height maximum 2 standard deviations of mean for age and gender) or inadequate growth deemed secondary to growth hormone deficiency (GHD) Naïve to growth hormone therapy  Known or suspected allergy to the trial product or related products Growth retardation attributable to causes other than GHD. Growth retardation attributable to diabetes mellitus, inborn errors of metabolism, primary bone disease, chromosomal disorders or disease of the genitourinary, cardiopulmonary, gastrointestinal or central nervous system; bone marrow transplantation or any syndrome known to give short stature (examples are: Prader-Willi Syndrome, Russell-Silver Syndrome, Turner Syndrome, Noonan Syndrome) Intrauterine growth retardation: birth weight below 3rd percentile, adjusted for gestational age Pregnancy or the intention to become pregnant Breast-feeding Administration of other growth-altering medication
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-11.0,  Genetic Disorder Turner Syndrome Turner Syndrome Well documented growth rate during the previous year Height below the 50th percentile for the age in Dutch children Normal thyroid function  Any endocrine or metabolic disorder Growth failure due to disorders of genitourinary, cardio-pulmonary, gastro-intestinal and nervous systems, nutritional/vitamins deficiencies and chondrodysplasias Patients with hydrocephalus
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 5.0-12.0,  Silver Russell Syndrome Prader-Willi Syndrome Patients with genetically proven SRS or PWS, under treatment with GH in the usual context of the disease, presenting with adrenarche (defined either by DHEAS levels as a function of age or by the appearance of pubic hair) associated with a bone age at least 6 months greater than chronological age and in the absence of the onset of central puberty (LH peak ≤ LH peak in prepubertal patients, according to the standards of the laboratory performing the GnRH stimulation test for LH and FSH, and dating back to less than 3 months) Patients with medical coverage The lower age limit for is 5 years and the upper age limit is 10 complete years for girls and 12 complete years for boys The maximum body-mass index (BMI) Z-score for is +4 Patients should be capable of swallowing pills of the same size as the experimental drug  Renal insufficiency (creatinine clearance, calculated according to the Schwartz formula, lower than 70ml/min/l, 73 m²) Hepatic insufficiency (prothrombin ratio < 50% and factor V < 50%) Hepatic cytolysis (liver transaminases levels greater than twice the normal level for age), cholestasis (gamma-glutamyl transferase (GGT) levels greater than twice the normal level for age) Contraindication to one of the components of Anastrozole or the placebo Patients with scoliosis requiring surgery
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Growth Hormone Disorder Growth Hormone Deficiency in Children Genetic Disorder Turner Syndrome Written Informed Consent by patient and/or guardian/parents Patients with one of the following diagnosis: Growth failure due to growth hormone deficiency (GHD), Turner syndrome, or growth retardation in children with chronic renal disorders Patients who are willing to inject themselves and answer questionnaires or young patients whose parents/guardian are willing to inject their child and answer questionnaires Patients on growth hormone therapy for at least 6 weeks before entering the trial  Pregnancy or breast feeding women Suspected or known allergy to trial product Other daily injection therapy (non-growth hormone, e.g insulin-therapy) Participating in any other trial involving other investigational products within the last 3 months
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-63.0,  Malnutrition Diarrhea Child Development (1) Infants (target child) will be eligible to participate in the study if they are: 1. They are in utero at the baseline survey 2. Their parents/guardians are planning to stay in the study village for the next 12 months (if a mother is planning to give birth at her natal home and then return, she will still be a candidate for enrollment) (2) Children < 36 months old at baseline that are living in the compound of a target child will be eligible to participate in diarrhea measurement if: 1. They are < 36 months old at the baseline survey 2. Their parents/guardians are planning to stay in the study village for the next 12 months (3) Children 18 months old at baseline that are living in the compound of a target child will be eligible to participate in intestinal parasite specimen collection if: 1. They are 18 months old at the baseline survey 2. Their parents/guardians are planning to stay in the study village for the next 12 months
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Mucopolysaccharidosis II A subject will be eligible for in this study only if patient meets 1 and 2 or 1 and 3 Diagnosed with Hunter syndrome Patients with Hunter syndrome who are being treated with idursulfase Patients with Hunter syndrome who are naïve of idursulfase treatment (if possible*) *This study will also attempt to recruit 1 patient who has never received idursulfase. If a naïve patient has not been identified within an agreed amount of time between GSK and the investigator, the study will concluded without this sample  Subjects who are currently participating in another clinical trial are not permitted to be enrolled in this study
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Growth Hormone Disorder Growth Hormone Deficiency in Children Genetic Disorder Turner Syndrome Growth hormone deficiency or short stature due to Turner Syndrome where the epiphyseal discs are not closed  Diabetic Patients with malignant tumors Women who are either pregnant or likely to be pregnant Known or suspected allergy to study product(s) or related products
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Growth Hormone Deficiency Turner Syndrome Chronic Renal Failure Small for Gestational Age Idiopathic Short Stature short stature children aged 2 years or more children with GHD,TS, CRF, SGA or ISS written informed consent from the person, person's parent or legal guardian
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-72.0,  Hypothermia Newborn Estimated gestational age 37 weeks and greater Birth weight greater than 2,500gms Delivery in the hospital  Infant admitted to the NICU Birth weight less than 2,500gms Abdominal wall defect or myelomeningocele Major congenital anomalies Blistering skin disorder
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 4.0-10.0,  Growth Hormone Deficiency have a height less than two standard deviations (SD) below the median height for individuals of the same age or height, a growth velocity (GV) ≤4 cm/yr, a GH peak concentration <7 ng/ml in two different provocative tests, a bone age (BA; ≤9 years in girls and ≤10 years in boys) at least 2 years less than his/her chronological age (CA);be in preadolescence (Tanner stage 1) and have a CA >3 years;have a height value recorded 3 months before the start of GH treatment to calculate pre-treatment GV; receive no prior GH treatment or stop the GH treatment for more than 4 weeks;sign informed consent  Patients with Liver and kidney dysfunction (ALT> upper limit of normal 2 times, Cr> upper limit of normal), hepatitis B virus detection, antigen-HBc, HBsAg and HBeAg are positive patients with known to a highly allergic constitution or allergic to the drug of this study Patients with diabetes, serious cardiopulmonary, blood system, malignant tumor and other diseases or systemic infection in immunocompromised and mental diseases Patients with other growth disorders, such as Turner syndrome, constitutional delay of growth and puberty, Laron syndrome, GH receptor deficiency, girls with growth delay have not ruled out chromosomal abnormalities Participated in clinical trials of other drugs in 3 months Other cases that the researchers considered unsuitable for this clinical trial
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 80.0-999.0,  Hypothyroidism Males and Females aged 80 years or older Diagnosed with hypothyroidism and treated with Levothyroxine for at least 6 months Living independently in the community All TSH results within the range 0.4 U/L in the 3 months before commencing the study Participant has provided written informed consent for participation in the study, prior to any study-specific procedures  Established dementia and therefore deemed incapable of providing informed consent Other medical conditions which, inthe opinion of the Chief Investigator, would prevent them from participating in the study (for example, end stage cancer, severe chronic health conditions where the patient is housebound) Nursing Homes or Residential Care Home residents Individuals with thyroid cancer: since they require high doses of LT4 to suppress their serum TSH Individuals on 25 mcg dailty of LT4: dose reduction will mean that they stop thyroid replacement treatment Non english speaking individuals Participation in any other investigational trials within the last 3 months Participants prescribed medications that can affect thyroid function (amiodarone, lithium, carbimazole or propylthiouracil) Known or suspected lactose intolerance (this would have implications for the proposed over-encapsulated IMP)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Gastric Cancer  Any patients age at GC cancer diagnosis was included. Male and female patients were either included. Healthy volunteers were not included. At the time of diagnosis of cancer patients must be a province of Cremona inhabitants (districts of Crema, Cremona or Casalmaggiore). Informed consent signature was required. TUMOR Diagnosis must be performed from 2010 Juanuary, the 1st to 2013 December, 31st .The diagnosis must be of a infiltrating malignant tumor. The diagnosis should be of a primary tumor. Precancerous diagnosis were not considered. Recidivate tumor were not considered. The site of localization of the tumor at diagnosis must be stomach or gastro - esophageal junction as site of tumor onset. HDGC : Gastric cancer is a known manifestation of inherited cancer predisposition syndromes similar to hereditary nonpolyposis colon cancer and Li-Fraumeni syndrome. According to the OMIM database, more than 90 per cent of gastric cancers are sporadic, whereas less than 10 per cent are hereditary (HDGC). Germline E-cadherin inactivating mutations in the CDH1 gene are responsible for the development of GC in approximately 30% of families with the hereditary diffuse gastric cancer syndrome (HDGC). Diagnostic for HDGC are formulated by the International Gastric Cancer Linkage Consortium in 1999 and then they are reviewed in 2010. In order to individuate HDGC case and to included them in a specialist counselling and CDH-1 gene mutation evaluation, by International GC Linkage Consortium 2010 guidelines were followed
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Turner Syndrome Klinefelter Syndrome Triple X Syndrome 47 XYY Syndrome Aortic Aneurysm Controls should fore fill the below Healthy Age matched  Any chronic or acute illness thought to influence the outcome measures